People

Paul Burney

Mentioned in 1 analyzed podcast episode across 1 show

Appears On

Episode Appearances

The Top Line

The Top Line · Jul 10, 2026

A $10B deal, China trial scrutiny and highlights from ADA 2026

Discussed Amgen's positioning as potential global leader in cardiometabolic risk management by 2030

Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyGLP-1 agonist efficacy and weight loss outcomes
View Analysis